<DOC>
	<DOCNO>NCT00340834</DOCNO>
	<brief_summary>This study assess safety , tolerability , efficacy 2 dose oral fingolimod versus interferon Î²-1a reduce frequency relapse patient relapsing-remitting multiple sclerosis .</brief_summary>
	<brief_title>Efficacy Safety Fingolimod Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Male female patient age 1855 diagnosis multiple sclerosis ( MS ) Patients relapsingremitting disease course Patients Expanded Disability Status Scale ( EDSS ) score 05.5 Patients chronic disease immune system , malignancy , acute pulmonary disease , cardiac failure , etc Pregnant nursing woman Patients tolerate treatment interferon Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FTY720</keyword>
	<keyword>Interferon</keyword>
	<keyword>RRMS</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Efficacy</keyword>
</DOC>